• 1
    Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquired Immune Defic Syndr 2000; 24: 211217.
  • 2
    Martin-Carbonero L, Soriano V, Valencia ME, Lopez M, Gonzalez-Lahoz J. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 14671471.
  • 3
    Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 14.
  • 4
    Bica I, McGovern B, Dhar L et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32: 492497.
  • 5
    Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis virus C in French departments of Internal Medicine/Infectious Diseases in 1995 and 1997. Clin Infect Dis 2001; 32: 12071214.
  • 6
    Rosenthal E, Poirée M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 18031809.
  • 7
    Rosenthal E, Pialoux G, Bernard N et al. Liver-related mortality in human immunodeficiency virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007; 14: 183188.
  • 8
    Chung R, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin vs. interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV co-infected persons. N Engl J Med 2004; 351: 451459.
  • 9
    Carrat F, Bani-Sadr F, Pol S et al. Pegylated-interferon alfa-2b vs. standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 28392848.
  • 10
    Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat 2006; 13: 678682.
  • 11
    Cacoub P, Halfon P, Rosenthal E et al. Treatment of hepatitis C virus in human immunodeficiency virus infected patients in ‘real life’: modifications in two large surveys between 2004 and 2006. J Hepatol 2008; 48: 3542.
  • 12
    Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the ‘Mortalité 2000 and 2005’ surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590598.
  • 13
    Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121130.
  • 14
    Ashley J. The international classification of diseases: the structure and content of the tenth revision. Health Trends 1990–1991; 22: 135137.
  • 15
    1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729730.
  • 16
    Salmon-Ceron D, Lewden C, Morlat P et al. Liver disease as a major cause of death in HIV-infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799805.
  • 17
    Camino X, Iribarren JA, Arrizabalga J, Rodriguez F, Von Wichmann AM. Causes of mortality among patients infected with the human immunodeficiency virus in the era of highly active antiretroviral therapy. Enferm Infecc Microbiol Clin 2001; 19: 8586.
  • 18
    Palella FJ, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era. Changing causes of death and disease in the HIV Outpatient Study. J Acquir Immun Defic Syndr 2006; 43: 2734.
  • 19
    Weber RS, Sabin CA, Friis-Møller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus. The D:A:D Study. Arch Intern Med 2006; 166: 16321641.
  • 20
    Torriani FJ, Rodriguez-Torres M, Rockstroh J et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 21
    Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97100.
  • 22
    Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005; 40 (Suppl. 5): S349S354.
  • 23
    Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 22852293.
  • 24
    Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 10541058.
  • 25
    Brau N, Fox RK, Xiao P et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47: 447450.
  • 26
    Kramer JR, Giordano TP, Souchek J et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in US veterans with hepatitis C. Am J Gastroenterol 2005; 100: 5663.
    Direct Link:
  • 27
    Degos F, Tural C. Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: is it really different, and if so, why? J Hepatol 2007; 47: 447450.
  • 28
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liv Transplant 2003; 9: 331338.
  • 29
    Pol S, Fontaine H, Carnot F et al. Predictive factors for cirrhosis development in parenterally-acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 1219.
  • 30
    Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological progression of hepatitis C infection. Hepatology 1998; 28: 805809.
  • 31
    Tsui JI, Saitz R, Cheng DM et al. Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV. J Gen Intern Med 2007; 22: 822825.
  • 32
    Nalpas B, Martin S, Fontaine H, Fabbro-Perret P, Bréchot C, Pol S. Impact of medical recommendations on alcohol consumption in HCV-positive patients. J Hepatol 2001; 35: 312313.
  • 33
    Larsen C, Pialoux G, Salmon D et al. Prévalence des co-infections par les virus des hépatites B et C dans la population VIH+, France, juin 2004. BEH 2005; 23: 109112.
  • 34
    Qurishi N, Kreuzberg C, Lüchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 17081713.
  • 35
    Kramer JR, Giordano TP, El-Serag HB. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol 2007; 5: 13211328.